高危弥漫性大B细胞淋巴瘤患者中Bcl-2蛋白频率
Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
作者信息
Hallack Neto Abrahão Elias, Siqueira Sheila Aparecida Coelho, Dulley Frederico Luiz, Chauobah Alfredo, Belesso Marcelo, Saboia Rosaura, Ruiz Milton Artur, Chamone Dalton Alencar Fischer, Pereira Juliana
机构信息
Department of Hematology, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
出版信息
Sao Paulo Med J. 2010 Jan;128(1):14-7. doi: 10.1590/s1516-31802010000100004.
CONTEXT AND OBJECTIVE
Gene expression and immunohistochemical profiling of diffuse large B-cell lymphoma (DLBCL) have revealed important prognostic subgroups: germinal center B-cell-like (GCB-like) DLBCL and activated B cell-like (ABC-like) DLBCL. Although few reports on high-risk DLBCL are available, the prognosis for the GCB-like subgroup has been shown to be better than that of the ABC-like subgroup. The role of Bcl-2 as a predictor of survival in DLBCL cases is unclear and its expression varies between the two subgroups of DLBCL. In this study, we analyzed the frequency and prognostic impact of Bcl-2 protein expression in high-risk DLBCL cases.
DESIGN AND SETTING
Retrospective cohort study among DLBCL patients treated at Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP).
METHODS
The prognostic impact of the expression of the proteins CD10, Bcl-6, MUM1 (multiple myeloma oncogene-1) and Bcl-2 on high-risk DLBCL cases was evaluated by means of immunohistochemistry. Seventy-three patients aged 18-60 years were evaluated for all these markers.
RESULTS
Twenty-four cases (32.9%) were GCB-like and 49 (67.1%) were ABC-like, with no difference regarding complete remission, disease-free survival or overall survival rates. Twenty-seven patients (37%) showed Bcl-2 expression, which was the only independent factor predicting a worse prognosis for overall survival according to multivariate analysis.
CONCLUSION
Bcl-2 protein was expressed in 37% of the high-risk DLBCL patients, without any difference between the ABC-like DLBCL and GCB-like DLBCL cases.
背景与目的
弥漫性大B细胞淋巴瘤（DLBCL）的基因表达和免疫组化分析揭示了重要的预后亚组：生发中心B细胞样（GCB样）DLBCL和活化B细胞样（ABC样）DLBCL。尽管关于高危DLBCL的报道较少，但已表明GCB样亚组的预后优于ABC样亚组。Bcl-2作为DLBCL病例生存预测指标的作用尚不清楚，且其在DLBCL的两个亚组中的表达有所不同。在本研究中，我们分析了高危DLBCL病例中Bcl-2蛋白表达的频率及其对预后的影响。
设计与研究地点
对圣保罗大学医学院临床医院（HC-FMUSP）治疗的DLBCL患者进行回顾性队列研究。
方法
通过免疫组化评估蛋白CD10、Bcl-6、多发性骨髓瘤癌基因1（MUM1）和Bcl-2的表达对高危DLBCL病例的预后影响。对73例年龄在18至60岁之间的患者进行了所有这些标志物的评估。
结果
24例（32.9%）为GCB样，49例（67.1%）为ABC样，在完全缓解率、无病生存率或总生存率方面无差异。27例患者（37%）表现出Bcl-2表达，根据多变量分析，这是预测总生存预后较差的唯一独立因素。
结论
37%的高危DLBCL患者表达Bcl-2蛋白，ABC样DLBCL和GCB样DLBCL病例之间无任何差异。
Zotero 插件